Guggenheim analyst Seamus Fernandez initiates coverage on Aclaris Therapeutis (NASDAQ: ACRS) with a Buy rating and a price target of $12.00.

For an analyst ratings summary and ratings history on Aclaris Therapeutis click here. For more ratings news on Aclaris Therapeutis click here.

Shares of Aclaris Therapeutis closed at $4.41 yesterday.